Evaluation of KRAS mutations, angiogenic biomarkers and DCE-MRI in patients with advanced non-small cell lung cancer receiving sorafenib

PURPOSE: Sorafenib, a multikinase inhibitor targeting Raf and VEGFR has shown activity in unselected patients with NSCLC. At present there are no validated biomarkers indicative of sorafenib activity. EXPERIMENTAL DESIGN: Patients received sorafenib 400mg bid daily to determine activity and tolerabi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kelly, Ronan J., Rajan, Arun, Force, Jeremy, Lopez-Chavez, Ariel, Keen, Corrine, Cao, Liang, Yu, Yunkai, Choyke, Peter, Turkbey, Baris, Raffeld, Mark, Xi, Liqiang, Steinberg, Seth M., Wright, John J., Kummar, Shivaani, Gutierrez, Martin, Giaccone, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3048919/
https://ncbi.nlm.nih.gov/pubmed/21224376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2331
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados